Huimei Capital

Total investments

25

Average round size

30M

Portfolio companies

20

Lead investments

4

Follow on index

0.20

Areas of investment
BiotechnologyHealth CareSaaSGeneticsManufacturingMedical DeviceMedicalLife SciencePharmaceuticalBiopharma

Summary

The fund is generally included in 2-6 deals every year. The top activity for fund was in 2019. Deals in the range of 10 - 50 millions dollars are the general things for fund.

Among the most successful fund investment fields, there are Health Care, Artificial Intelligence. Among the various public portfolio startups of the fund, we may underline Huimei Technology Besides, a startup needs to be aged 4-5 years to get the investment from the fund.

The standard case for the fund is to invest in rounds with 4-5 partakers. The meaningful sponsors for the fund in investment in the same round are WuXi AppTec, Sherpa Venture Capital, Qiming Venture Partners.

Show more

Investments analytics

Analytics

Total investments
25
Lead investments
4
Follow on index
0.20
Investments by industry
  • Health Care (12)
  • Medical (10)
  • Biotechnology (9)
  • Medical Device (6)
  • SaaS (4)
  • Show 19 more
Investments by region
  • China (22)
  • Japan (1)
  • United States (2)
Peak activity year
2022

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
8
Group Appearance index
0.88

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Chengdu Pukang Biotechnology Co. 06 Jun 2024 Early Stage Venture Sichuan, Chengdu, China
Proton Bio 19 Aug 2022 Biotechnology, Medical, Biopharma Early Stage Venture 80M Jiangsu, Suzhou, China
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.